10 Conclusions and clinical take-home messages 10.1 Main findings: certainties amidst uncertainties Synthesizing the current evidence, the information architecture regarding GLP-1RAs in PCOS fertility management exhibits a characteristic gradient: robust metabolic evidence, hypothesis-generating reproductive findings, and a gray zone of safety. Robust metabolic benefit: in overweight or obese PCOS phenotypes, evidence for the improvement of metabolic endpointsincluding body weight, central adiposity, and IRis consistently positive, facilitating the establishment of actionable therapeutic goals (e.g., reaching clinically significant weight-loss thresholds and optimizing IR markers)
Draw the intended dose for that peptide, then check for air bubbles and push any out
Co-infusion of GLP-1 and GCG has been shown to reduce glucagon-induced hyperglycemia, lower blood glucose levels, suppress food intake, and enhance energy expenditure in both diabetic obese mice and healthy human volunteers [78]
That is the test that matters, and sublingual does not pass it reliably
